Stockscreener 앱 받기
10.68
4.30%
-0.48
시간 외 거래:
10.68
전일 마감가:
$11.16
열려 있는:
$11.1
하루 거래량:
111.81K
Relative Volume:
0.61
시가총액:
$581.03M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-9.95%
1개월 성능:
-15.91%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$10.46
$11.60
1주일 범위
$10.46
$12.56
52주 변동 폭
$10.37
$13.50
Alumis Inc Stock (ALMS) Company Profile
명칭
Alumis Inc
전화
650-231-6625
주소
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Alumis Inc 주식(ALMS)의 최신 뉴스
Alumis (NASDAQ:ALMS) Trading Down 4.8% - MarketBeat
Alumis reports progress in psoriasis treatment trial By Investing.com - Investing.com South Africa
Alumis reports progress in psoriasis treatment trial - Investing.com India
Alumis reports progress in psoriasis treatment trial By Investing.com - Investing.com Canada
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study - The Manila Times
ALMSAlumis Inc. Latest Stock News & Market Updates - StockTitan
Alumis (NASDAQ:ALMS) Trading Up 4.8% - MarketBeat
(ALMS) Technical Data - Stock Traders Daily
Alumis (NASDAQ:ALMS) Shares Gap Down to $11.86 - Defense World
Alumis (NASDAQ:ALMS) Shares Gap Down to $11.86 - MarketBeat
Yu Fan Purchases New Stake in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis Inc. [ALMS] Stock bought by Insider Foresite Labs, LLC for $40.0 million - Knox Daily
Taking on analysts’ expectations and winning: Alumis Inc. (ALMS) - SETE News
SR One Capital Management LP Invests $26.07 Million in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis (NASDAQ:ALMS) Shares Down 2.6% - MarketBeat
Alumis (NASDAQ:ALMS) Trading 5.3% Higher - MarketBeat
Alumis (NASDAQ:ALMS) Stock Price Up 5.3% - Defense World
Alumis (NASDAQ:ALMS) Reaches New 12-Month Low at $10.37 - MarketBeat
Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases (NASDAQ:ALMS) - Seeking Alpha
Vatroslav Mateljic Appointed General Manager of Takeda Canada - Quantisnow
Objective long/short (ALMS) Report - Stock Traders Daily
TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut - Reuters
Alumis (NASDAQ:ALMS) Shares Up 8.6% - MarketBeat
Alumis (NASDAQ:ALMS) Stock Price Down 4.6% - MarketBeat
Psoriasis Market is anticipated to rise at a notable CAGR, estimates DelveInsight | Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb - Barchart
Biotech IPO Hopefuls Ready Burst of Debuts After Rough Stretch - BNN Bloomberg
Alumis (NASDAQ:ALMS) Shares Gap Up to $12.20 - MarketBeat
Alumis to Participate in Upcoming September Investor Conferences - ForexTV.com
Understanding the Risks of Investing in Alumis Inc. (ALMS) - Knox Daily
Recent Insider Activity Suggests Potential Gains for Sezzle Inc. (SEZL) - Knox Daily
(ALMS) On The My Stocks Page - Stock Traders Daily
Alumis (NASDAQ:ALMS) Shares Down 4.8% - Defense World
Alumis (NASDAQ:ALMS) Shares Down 4.8% - MarketBeat
Cantor Fitzgerald Equities Analysts Lift Earnings Estimates for Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis Inc. (NASDAQ:ALMS) Forecasted to Earn FY2024 Earnings of ($5.67) Per Share - Defense World
Cantor Fitzgerald Reiterates Overweight Rating for Alumis (NASDAQ:ALMS) - MarketBeat
Q3 2024 EPS Estimates for Alumis Inc. Decreased by Leerink Partnrs (NASDAQ:ALMS) - MarketBeat
Alumis (NASDAQ:ALMS) Shares Gap Down to $12.54 - MarketBeat
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements - BioSpace
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and - The Bakersfield Californian
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements - wallstreet:online
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements - ForexTV.com
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements - StockTitan
(ALMS) Trading Report - Stock Traders Daily
Q&A: Alumis Inc. Initiates Phase 3 Clinical Program for ESK-001 in Plaque Psoriasis - Dermatology Times
Checking in on Alumis Inc. (ALMS) after recent insiders movement - Knox Daily
Alumis Inc.'s Quiet Period Set To End on August 7th (NASDAQ:ALMS) - MarketBeat
Telomir Pharmaceuticals, Inc.’s Lock-Up Period Will Expire on August 7th (NASDAQ:TELO) - Defense World
BBB Foods Inc.’s Lock-Up Period Will Expire on August 7th (NYSE:TBBB) - Defense World
Alumis (NASDAQ:ALMS) Stock Price Down 5.9% - MarketBeat
Potential Competitor To BMS’s Sotyktu Bites The Dust - Scrip
Alumis Inc (ALMS) 재무 분석
Alumis Inc (ALMS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.05%
4.86%
자본화:
|
볼륨(24시간):